secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0001193125-25-019256
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Therapeutics appoints Lesley Ann Calhoun as COO while retaining CFO role
-------------------------------------------------------------------------------

- Lesley Ann Calhoun appointed COO effective January 30, 2025, adding to existing CFO role.
- She has served as EVP and CFO since June 2020; prior roles at Global Blood Therapeutics and Hyperion Therapeutics.
- Calhoun brings over 30 years of finance and operations experience, including audit at Deloitte & Touche.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312525019256/0001193125-25-019256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312525019256/d860038d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-019256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer